The cholinergic system in the pathophysiology and treatment of Alzheimer's disease

dc.contributor.authorHampel, Harald
dc.contributor.authorMesulam, M.-Marsel
dc.contributor.authorCuello, A. Claudio
dc.contributor.authorFarlow, Martin R.
dc.contributor.authorGiacobini, Ezio
dc.contributor.authorGrossberg, George T.
dc.contributor.authorKhachaturian, Ara S.
dc.contributor.authorVergallo, Andrea
dc.contributor.authorCavedo, Enrica
dc.contributor.authorSnyder, Peter J.
dc.contributor.authorKhachaturian, Zaven S.
dc.contributor.departmentNeurology, IU School of Medicineen_US
dc.date.accessioned2019-09-05T18:50:57Z
dc.date.available2019-09-05T18:50:57Z
dc.date.issued2018-07
dc.description.abstractCholinergic synapses are ubiquitous in the human central nervous system. Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions. Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity. As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease. The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation. Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation. Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease. This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins. This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies. The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.en_US
dc.identifier.citationHampel, H., Mesulam, M. M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., … Khachaturian, Z. S. (2018). The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain : a journal of neurology, 141(7), 1917–1933. doi:10.1093/brain/awy132en_US
dc.identifier.urihttps://hdl.handle.net/1805/20813
dc.language.isoen_USen_US
dc.publisherOxford University Pressen_US
dc.relation.isversionof10.1093/brain/awy132en_US
dc.relation.journalBrain : a journal of neurologyen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectAcetylcholineen_US
dc.subjectAlzheimer’s diseaseen_US
dc.subjectCholinergic systemen_US
dc.subjectCholinesterase inhibitorsen_US
dc.subjectCognitionen_US
dc.titleThe cholinergic system in the pathophysiology and treatment of Alzheimer's diseaseen_US
dc.typeArticleen_US
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022632/en_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
awy132.pdf
Size:
357.79 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: